Calquence

Chemical Nameacalabrutinib
Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyAstraZeneca
Approval Year2017

Indication

  • Calquence is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
  • Calquence is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Last updated on 2/3/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Calquence (acalabrutinib) Prescribing Information.2019AstraZeneca
Document TitleYearSource
Phramacoeconomic report: acalabrutinib (calquence).2020CADTH
Clinical report: acalabrutinib (calquence).2020CADTH
Acalabrutinib for treating chronic lymphocytic leukaemia.2020The School of Health and Related Research, The University of Sheffield